← Search

Data · dataset · 2026

miRNA profile in HeFH and non-FH patients treated with PCSK9 inhibitor

Listed in Teesside University Research Data Repository

Our study aimed to characterize changes in the circulating miRNome during one year of treatment with the monoclonal antibodies alirocumab or evolocumab and to compare these changes between HeFH patients and non-FH patients.

Description

We hypothesized that PCSK9i therapy would induce distinct alterations in circulating miRNA profiles reflecting differences in lipid metabolism, inflammatory signaling, and cardiovascular risk-related pathways between HeFH and non-FH patients.

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 8 field assertions
SourceKeyLast seenRaw
Teesside University Research Data Repositoryoai:data.mendeley.com/92gnf9vdd6.119 h agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
concepts[field].anzsrc:field:310504mapping · researchdata tees ac ukvocabulary-mapper@1.0.0keywords['Epigenetics']
concepts[field].local:field:earth-environmentalmapping · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
descriptionsource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/description
licensesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/rights
publication_datesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0
titlesource · researchdata tees ac ukconnector:researchdata_tees_ac_uk@1.0.0/metadata/dc/title